



## Stoke Therapeutics to Present at Upcoming Investor Conferences in September

September 3, 2024

BEDFORD, Mass.--(BUSINESS WIRE)--Sep. 3, 2024-- [Stoke Therapeutics, Inc.](https://www.stoketherapeutics.com) (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that management will present at the following upcoming investor conferences:

### H.C. Wainwright 26th Annual Global Investment Conference

**Date:** Tuesday, September 10, 2024

**Time:** 12:00 p.m. ET

### 2024 Cantor Fitzgerald Global Healthcare Conference

**Date:** Tuesday, September 17, 2024

**Time:** 11:30 a.m. ET

Live webcasts of each event and an archived replay of the webcasts following each event, will be available on the Investors & News section of Stoke's website at <https://investor.stoketherapeutics.com/>.

### About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke's first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke's initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit <https://www.stoketherapeutics.com/>.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240903002278/en/): <https://www.businesswire.com/news/home/20240903002278/en/>

### Stoke Investor Contact:

Doug Snow

Director, Communications & Investor Relations

[IR@stoketherapeutics.com](mailto:IR@stoketherapeutics.com)

508-642-6485

Source: Stoke Therapeutics, Inc.